The article discusses an Expression of Concern issued by Anticancer Research regarding the Hulscher et al. study on ivermectin and mebendazole. It highlights data verifiability issues, the authors’ conflicts of interest tied to The Wellness Company, and how this study differs from credible cancer research, ultimately urging caution for patients evaluating such claims.
Category: Evaluating Cancer Treatment Claims
What Oncologists and Evidence-Based Medicine Say About Ivermectin for Cancer Right Now
Courage Against Cancer clarifies that ivermectin lacks validated clinical evidence as a cancer treatment despite preclinical interest. Major oncology institutions do not endorse it, emphasizing the importance of rigorous evidence-based evaluations. Patients are encouraged to discuss concerns with their oncologists and critically assess claims surrounding off-label treatments.
The Joe Tippens Story: How a Veterinary Dewormer Became a Viral Cancer Cure Claim
The article from Courage Against Cancer discusses Joe Tippens, whose recovery from small cell lung cancer was linked to fenbendazole, a veterinary dewormer. It emphasizes that his case lacks clinical validation and critical context, such as concurrent immunotherapy, highlighting the importance of distinguishing personal narratives from scientific evidence in cancer treatment discussions.
What Is the Best Cancer Treatment for My Type and Stage of Cancer?
Courage Against Cancer emphasizes the importance of personalized cancer treatment plans, tailored based on cancer type, stage, and individual patient factors. This guide details various treatment modalities, including chemotherapy, radiation, immunotherapy, hormone therapy, and stem cell transplants, while encouraging patients to engage with their healthcare teams for informed decisions.
The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known
Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.
How Cancer Patients and Caregivers Should Evaluate Viral Claims About Unproven Treatments
The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.
NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things
Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.
Is Ivermectin approved by the FDA as a cancer treatment for any type of cancer?
As of 2026, the FDA has not approved ivermectin for any cancer treatments; it is only sanctioned for specific parasitic infections. While off-label prescribing is legal, there is no solid evidence supporting its efficacy in oncology. Patients should consult their healthcare providers before altering treatment plans based on unverified claims.
The Wellness Company Study of Ivermectin and Mebendazole Review
A study conducted by Dr. Nicolas Hulscher at the Wellness Company examined the effects of compounded Ivermectin and Menebedazole on 197 cancer patients over six months. While results appear promising, concerns arise regarding the study’s methodology, raising questions about the necessity of formal clinical trials for FDA consideration.
How do treatment plans differ between early-stage and advanced cancer?
Cancer treatment strategies vary based on the cancer stage. Early-stage treatments aim for a cure, using surgery, radiation, and targeted therapy. Advanced cancers focus on disease management through chemotherapy and immunotherapy, prioritizing quality of life. Oncology teams customize plans according to diagnosis, health status, and patient preferences, with ongoing advancements offering new options.
